INTERNATIONAL PATENT: CRISPR THERAPEUTICS AG FILES APPLICATION FOR "GENETICALLY MODIFIED CELLS EXPRESSING GLP-1 RECEPTOR AGONIST"

GENEVA, Oct. 4 -- CRISPR THERAPEUTICS AG (Baarerstrasse 146300 Zug) filed a patent application (PCT/IB2025/053108) for "GENETICALLY MODIFIED CELLS EXPRESSING GLP-1 RECEPTOR AGONIST" on Mar 24, 2025. With publication no. WO/2025/202874, the details related to the patent application was published on Oct 02, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): LIAO, Meichen (105 West First StreetSouth Boston, Massachusetts 02127)

Abstract: Disclosed herein include methods, compositions, and kits suitable for use in treating diseases or disorders related to insulin signaling. In some embodiments, th...